Compare Citius Pharmaceuticals Inc (CTXR) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 7801.8× Citius Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Starbucks Corp for 190 Days on average.
| CTXR | SBUX | |
|---|---|---|
Market Cap | $13.62M | $106.26B |
Volume | 132,438 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $108.55 |
52-Week Low | $0.48 | $78.46 |
Typical Hold Time | 17 Days | 190 Days |
Enterprise Value | $3.79M | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Starbucks (SBUX) trades at $93.21, down 0.4% with bearish technical signals. Recent earnings show mixed results with Q2 2026 beating expectations but Q4 2025 missing. The company is undergoing strategic restructuring with 250 store closures announced in September 2026, while maintaining dividend payments. Revenue growth remains modest at $37.18B for 2025 with net income margin at 5.17%. Analyst consensus remains positive with a $115.50 price target despite current bearish technical indicators.
SBUX presents a turnaround opportunity with strong analyst support but faces execution risks from store closures and competitive pressures. The stock trades at premium valuations (P/E 53.88) requiring sustained earnings growth. Near-term volatility expected during restructuring, while long-term prospects depend on successful portfolio optimization and international expansion, particularly in Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
